Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada
Abstract Background Treatment guidelines suggest either a low-dose or high-dose approach when prescribing amikacin for nontuberculous mycobacterial pulmonary disease (NTM PD), but data supporting the low-dose approach are limited. The purpose of this study was to describe the safety and efficacy of...
Saved in:
Main Authors: | Maria Luisa Aznar (Author), Theodore K. Marras (Author), Ahmed Said Elshal (Author), Mahtab Mehrabi (Author), Sarah K. Brode (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2019-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Population Pharmacokinetic Analysis of Amikacin for Optimal Pharmacotherapy in Korean Patients with Nontuberculous Mycobacterial Pulmonary Disease
by: Xuanyou Jin, et al.
Published: (2020) -
The Use of Amikacin Liposome Inhalation Suspension (Arikayce) in the Treatment of Refractory Nontuberculous Mycobacterial Lung Disease in Adults
by: Khan O, et al.
Published: (2020) -
Imaging characteristics of nontuberculous mycobacterial pulmonary nodules
by: Nishino Kengo, et al.
Published: (2021) -
Occurrence of nontuberculous mycobacterial pulmonary infection in an endemic area of tuberculosis.
by: Ana Roberta Fusco da Costa, et al.
Published: (2013) -
Pulmonary Nontuberculous Mycobacterial Infection in Infants: A Systematic Review
by: Bai A, et al.
Published: (2021)